Last Price Today's Change   Day's Range   Trading Volume
0.64   +0.005 (0.79%)  0.625 - 0.645  447,000
Analyze this stock with MQ Trader system

Recent Prices

Date Open Range Close Change Volume
15/11/2019 0.62 0.62 - 0.64 0.635 +0.02 (3.25%) 337,100
14/11/2019 0.625 0.61 - 0.63 0.615 -0.005 (0.81%) 621,700
13/11/2019 0.635 0.615 - 0.635 0.62 -0.015 (2.36%) 668,800
12/11/2019 0.655 0.63 - 0.655 0.635 -0.01 (1.55%) 378,600
11/11/2019 0.66 0.63 - 0.66 0.645 -0.005 (0.77%) 523,000
08/11/2019 0.65 0.64 - 0.665 0.65 +0.01 (1.56%) 2,524,100
07/11/2019 0.61 0.60 - 0.65 0.64 +0.025 (4.07%) 3,114,900
06/11/2019 0.605 0.60 - 0.615 0.615 +0.005 (0.82%) 308,800
05/11/2019 0.605 0.60 - 0.615 0.61 +0.005 (0.83%) 734,600
04/11/2019 0.62 0.605 - 0.62 0.605 -0.015 (2.42%) 1,053,700
01/11/2019 0.625 0.61 - 0.625 0.62 -0.005 (0.80%) 554,100
31/10/2019 0.61 0.61 - 0.63 0.625 +0.01 (1.63%) 1,201,400
30/10/2019 0.62 0.60 - 0.62 0.615 -0.005 (0.81%) 1,509,100
29/10/2019 0.64 0.615 - 0.645 0.62 -0.015 (2.36%) 1,588,600
25/10/2019 0.635 0.63 - 0.64 0.635 0.00 (0.00%) 680,100
24/10/2019 0.65 0.635 - 0.65 0.635 -0.01 (1.55%) 594,700
23/10/2019 0.65 0.64 - 0.67 0.645 -0.005 (0.77%) 1,813,300
22/10/2019 0.64 0.635 - 0.67 0.65 +0.015 (2.36%) 2,940,800
21/10/2019 0.62 0.615 - 0.65 0.635 +0.015 (2.42%) 1,019,000
Trade this stock and win a FREE I3investor T-shirt after 5 trades. Find out more.

  Be the first to like this.
shortinvestor77 Nova uses Phyllanthus niruri (dukung anak) (easily found in Malaysia) for Hepar-P capsule.
Liver care is as complex as the liver itself. Hepar-P is a natural liver tonic agent, formulated with a standardized extract of Phyllanthus niruri and holds two Malaysian patents. Hepar-P provides a consistent dose of the functional actives, responsible for protecting the liver from injury.
11/10/2019 5:40 PM
Up_down It may take years to get through 5 phases clinical trials .

Phases of clinical trials
A clinical trial is only done when there is good reason to believe that a new test or treatment may improve the care of patients. Before clinical trials, tests and treatments are assessed in preclinical research. Preclinical research is not done with people. It assesses the features of a test or treatment. For example, the research may aim to learn if a device is harmful to living tissue. Another aim may be to learn more about the chemical makeup of a drug.

After preclinical research, tests and treatments go through a series of clinical trials. Clinical trials assess if tests or treatments are safe for and work in people. Clinical trials have five phases. The phases are described next using the example of a new drug treatment:

Phase 0
Phase 0 trials are the first clinical trials done among people. They aim to learn how a drug is processed in the body and how it affects the body. In these trials, a very small dose of a drug is given to about 10 to 15 people.

Phase I
Phase I trials aim to find the best dose of a new drug with the fewest side effects. The drug will be tested in a small group of 15 to 30 patients. Doctors start by giving very low doses of the drug to a few patients. Higher doses are given to other patients until side effects become too severe or the desired effect is seen. The drug may help patients, but Phase I trials are to test a drug’s safety. If a drug is found to be safe enough, it can be tested in a phase II clinical trial.

Phase II
Phase II trials further assess safety as well as if a drug works. The drug is often tested among patients with a specific type of cancer. Phase II trials are done in larger groups of patients compared to Phase I trials. Often, new combinations of drugs are tested. Patients are closely watched to see if the drug works. However, the new drug is rarely compared to the current (standard-of-care) drug that is used. If a drug is found to work, it can be tested in a phase III clinical trial.

Phase III
Phase III trials compare a new drug to the standard-of-care drug. These trials assess the side effects of each drug and which drug works better. Phase III trials enroll 100 or more patients.

Often, these trials are randomized. This means that patients are put into a treatment group, called trial arms, by chance. Randomization is needed to make sure that the people in all trial arms are alike. This lets scientists know that the results of the clinical trial are due to the treatment and not differences between the groups. A computer program is often used to randomly assign people to the trial arms.

There can be more than two treatment groups in phase III trials. The control group gets the standard-of-care treatment. The other groups get a new treatment. Neither you nor your doctor can choose your group. You will also not know which group you’re in until the trial is over.

Every patient in a phase III study is watched closely. The study will be stopped early if the side effects of the new drug are too severe or if one group has much better results. Phase III clinical trials are often needed before the FDA will approve the use of a new drug for the general public.

Phase IV
Phase IV trials test new drugs approved by the FDA. The drug is tested in several hundreds or thousands of patients. This allows for better research on short-lived and long-lasting side effects and safety. For instance, some rare side effects may only be found in large groups of people. Doctors can also learn more about how well the drug works and if it’s helpful when used with other treatments.
11/10/2019 6:07 PM
Up_down If Hepar-P is able to complete 3rd clinical trials, MNC may come to take over Nova. lolz

Posted by shortinvestor77 > Oct 11, 2019 5:32 PM | Report Abuse

Clinical trial of Hepar-P Capsule ( is for the treatment of non-alcoholic fatty liver disease.
Completed the first clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
Ready for the second clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
11/10/2019 6:21 PM
shortinvestor77 Nova Wellness bosses have a large portion of shares, unabled to be taken over easily by multi national companies lah. Anyhow, they can start buying now aa you can see the share price is uptrend.
11/10/2019 9:41 PM
Armada An Quantum Leap Stock In 2019/2020 Up down sifu
Give you 1 like
For the facts sharing
11/10/2019 9:48 PM
Up_down Share price up like nobody business. First TP 76 cents.
14/10/2019 11:12 AM
15/10/2019 10:01 AM
CASHCOWINVESTOR Buy before regret
15/10/2019 10:10 AM
Armada An Quantum Leap Stock In 2019/2020 Today closing at 0.630 

Firm support at 0.600 
Immediate target to hit 0.710 

Risk over Reward : 1 to 3 
The probability of win is more than your meal for a day. 
In another word, entry at 0.630 u chance to win just like eating lettuce. 

17/10/2019 12:55 AM
17/10/2019 6:29 PM
cheer76 topup
17/10/2019 11:10 PM
Armada An Quantum Leap Stock In 2019/2020 Nova making a return again
Real good
18/10/2019 9:58 AM
Up_down Financial facts of Nova Wellness:
Price: 0.64
PER: 21x
Gearing: Nil
Dividend yield: 3.6% ( 2.3 cents per share)

Net cash generated from operating activities:
FY 30 Jun 2019 - 13.3m
FY 30 Jun 2018 - 7.1m

30 Sep 19 - ???
30 Jun 19 - 3.71m ( excluding IPO expenses, reversal of slow moving stock & interest received)
31 Mar 19 - 2.03m
31 Dec 18 - 3.08m
30 Sep 18 - 0.85m
30 Jun 18 - 2.41m
31 Mar 18 - 1.38m

30 Sep 19 - ???
30 Jun 19 - 9.6m
31 Mar 19 - 7.2m
31 Dec 18 - 7.9m
30 Sep 18 - 4.8m
30 Jun 18 - 8.1m
31 Mar 18 - 4.7m
18/10/2019 11:09 AM
LiimInvest Turnover
30 Sep 19 - ??? sure increase
21/10/2019 5:15 PM
cheer76 80cents please
21/10/2019 7:47 PM
Up_down Extract from prospectus:

2nd clinical trial:
We initiated the second clinical trial for Hepar-P Capsule in December 2017 and are expected to complete in December 2019. The second clinical trial is to allow for a specific claim on the effectiveness of Hepar-P Capsule for the improvement of liver health. The second trial involves patients with non-alcoholic fatty liver as well and will be administered to a larger group of participants of approximately 200 participants to further evaluate its effectiveness for liver health.

3rd clinical trial:
Third clinical trial for Hepar-P Capsule as liver protection agent;
We expect to begin the third clinical trial for Hepar-P Capsule in October 2019 and to complete in December 2020. The third clinical trial involves patients with drug induced liver injury. The third clinical trial will be administered to a larger group of participants of approximately 300 participants to further evaluate the product’s effectiveness. The third clinical trial will be a 6-month trial involving participants with elevated liver enzymes level. If the trial is successful and Hepar-P Capsule is clinically proven to be effective, the third clinical trial will allow for more empirical data to be obtained to further promote and strengthen the product positioning as a liver protection agent.
22/10/2019 11:07 AM
22/10/2019 1:21 PM
22/10/2019 2:33 PM
Up_down 1st clinical trial:

The first clinical trial was completed in January 2015. Our CRO has presented us the final report of the study. From the first clinical trial, Hepar-P Capsule was proven was proven safe for long term consumption with no adverse effects reported in patients. However, the efficacy could not be concluded as not all the patients consented to the liver biopsy at the end of the clinical trial. Only 6 patients out of the 50 patients consented to repeat the liver biopsy at the end of the clinical trial. The 6 patients showed improvement in liver enzymes. The major limitation of the first clinical trial is the relatively small sample size (50 patients) and the biopsy was not repeated for most of the patients after the completion of the treatment.
22/10/2019 2:47 PM
kkwn1718 May I know how was the performance of Nova in past two weeks?
22/10/2019 8:46 PM
Samtuckfatt Kkwn1718.

https://www.klsescreener.com/v2/stocks/view/0201 , click the historical price
22/10/2019 11:36 PM
Up_down New GMP factory:
Upon completion of the new GMP-compliant production facility, our production capacity for functional food is expected to increase from 0.69 million bottles and 0.69 million sachets to 3.43 million bottles and 3.43 million sachets.

The construction of the new GMP Plant had commenced in August 2017 and Phase 1 is expected to be completed by September 2019. Construction of Phase 2 will commence after completion of Phase 1.

Clinical trials on Ficus Cream products for skin lightening and We have completed the pre-clinical trial on Ficus microcarpa standardised extract contained in Ficus Cream products in 2016. We intend to undertake two clinical trials for Ficus Cream products in September 2019 and to complete both by July 2020. The clinical trials are to evaluate the effectiveness and safety of Ficus Cream for skin lightening and to explore other anti-ageing properties. The trials will be conducted on two different formulations containing the Ficus microcarpa standardised extract. Each clinical trial will be an 8-week trial and will involve a group of approximately 50 participants.

If the trials are successful and Ficus Cream products are clinically proven to be effective and safe for skin lightening, we expect to strengthen the products positioning as a skin lightening agent.
23/10/2019 2:38 PM
LiimInvest Up_down-thanks for your sharing. Great info.
23/10/2019 5:29 PM
Up_down https://clinicalresearch.my/the-journey-of-a-clinician-researcher-on-nafld-in-malaysia-from-epidemiology-to-non-invasive-assessment-to-treatment/

Epidemiology of NAFLD

The prevalence of NAFLD in the general population was estimated to be 23% based on a study using ultrasonography on health check individuals in a private medical centre in Petaling Jaya about a decade ago.(2)“The work by Professor Dato Dr. Goh Khean Lee and his colleagues, provided primary data on the estimated prevalence of NAFLD in the general population in Malaysia,” said Dr. Chan. Recently, the prevalence of NAFLD was found to be 57% based on a study using Fibroscan on health check individuals in a public medical facility in Kuala Lumpur. The study also found that 18% of the individuals had liver stiffness measurement consistent with excessive scarring in the liver.(3)“The figures from our latest work are indeed worrisome. More concerted efforts are needed to tackle obesity and obesity-related disease such as NAFLD,” he said. The group also reported that half of the patients with diabetes mellitus seen at their hospital clinic had NAFLD,(4)and 8% of the students at their faculty had NAFLD.(5)
23/10/2019 8:02 PM
Up_down Dealing with fatty liver

" More new drugs emerge ever day, but even promising ones such as glucagon-like-peptide-1 receptor agonist are still in testing or trail stages....
23/10/2019 8:16 PM
25/10/2019 11:28 PM
Hew Kiong Peng George ronnie tang invest 3k plus lots in nova base on 2019 annual report
30/10/2019 6:29 AM
kent_1 Even if this coming quarter EPS 1.5, the PE will be 12++ only. IPO was 0.55, i think with net profit increased this much, current price is a steal.
30/10/2019 1:41 PM
Up_down Awaiting the company to announce better QR next month and completion of 2nd clinical trials for Herpa-P early next year.
30/10/2019 1:59 PM
shortinvestor77 AR:
The nutraceutical industry in Malaysia stood at RM98.77 billion in 2017and has a forecast compound annual growth rate ("CAGR") of 2.5% from 2018 to 2022 with revenue projected to reach RM111.51 billion in 2022.
Based on the above positive outlook of the Malaysian nutraceutical industry and barring any unforseen circumstances, we believe that the Group's prospect in the next financial year ending 30 June 2020 remains positive.
30/10/2019 9:46 PM
kent_1 Added some at 0.605 lets hope to get more below 0.6. ;)
05/11/2019 8:19 AM
kent_1 Got some movement today. ;)
07/11/2019 11:52 AM
Up_down Rebound so fast. Yoyo game?
07/11/2019 12:04 PM
shortinvestor77 Fungs accumulating for so long will push up higher.
07/11/2019 1:35 PM
Up_down According to AR 2019. Nova is tightly held by 20 individuals plus Phillip Capital for 88% of the shareholding. It's up to them to make a call.
07/11/2019 2:06 PM
kent_1 Volume today thus far is the sum of the past 4 days...
07/11/2019 3:21 PM
shortinvestor77 IT WILL BREAK 0.70 not far from now.
07/11/2019 8:44 PM
Armada An Quantum Leap Stock In 2019/2020 U see 0.640
U see it no more soon.

Lets march 0.735 first.
08/11/2019 6:29 AM
Armada An Quantum Leap Stock In 2019/2020 Up down sifu
On guardian here... i can feel strong confidence
08/11/2019 6:30 AM
Up_down VenFx. It’s now much dependent on QR and Herpa-P clinical tests. If Nova is able to complete 3rd clinical test next year, it may trade PER above 30x.
08/11/2019 10:44 AM
kent_1 Even if the coming QR with lower coming quarter EPS 1.5, the PE will be 13.5++ only with current price 0.66. IPO was 0.55, i think with net profit increased this much, current price is a steal.
08/11/2019 11:11 AM
LiimInvest I feel strong confidence too
08/11/2019 2:12 PM
Goinvest88 I have no confidence with coming QR, sceptical any seasonal factor in QR
09/11/2019 6:39 AM
Up_down Believe that Nova Revenue is sustainable. Here's the information in AR.

Extracted from AR 2019:

- FY 2019 - New products were launched into the market including Nova Enzymes tablets, Nova AstaOmega 3 Softgel, Sustinex Vegetable Oil Blend Powder & Nova ALA-SR 300mg tablet.
- Nova Wellness Partner Programme (NWPP) increased from 112 to 118.
- NWPP outlets up from 220 to 243
- Increased in Herpa-P sales from 2nd clinical trials.
09/11/2019 2:22 PM
LiimInvest Thanks @ Up_down
09/11/2019 10:46 PM
kent_1 Let see if i have the chance to collect at below 0.6 ;)
13/11/2019 2:09 PM
Armada An Quantum Leap Stock In 2019/2020 Up_down sifu very focus in here.

Add position before another spike beyond 0.650
15/11/2019 10:25 AM
Armada An Quantum Leap Stock In 2019/2020 Nova will be next
After Fpgroup.

This 2 also chasing each other.
15/11/2019 4:47 PM
Up_down VenFx. Last QR, Nova has reported highest turnover in a quarter even without increasing in Debtor. Cash inflow is quite healthy. It means the management did not push up in sales the final quarter as they did last year. Anyway, it is hard to say in stock market. lolz.
18/11/2019 5:13 PM
Armada An Quantum Leap Stock In 2019/2020 Yaa , Up bro

noticed that too.
18/11/2019 7:56 PM


367  299  549  784 

Top 10 Active Counters
 SAPNRG 0.300.00 
 ARMADA 0.5250.00 
 BORNOIL 0.0450.00 
 HSI-H8F 0.335-0.085 
 MLAB 0.06-0.005 
 HHGROUP 0.06-0.015 
 HSI-C7K 0.375+0.06 
 NETX 0.025+0.005 
 TRIVE 0.015+0.005 
 VELESTO 0.385+0.005 
Partners & Brokers